Background: Chronic Q fever is accompanied by high mortality and morbidity, and requires prolonged antibiotic treatment. Little is known on long-term quality of life (LQOL) in chronic Q fever patients treated with antibiotics. Aim: To identify patient and treatment-related factors associated with impaired LQOL in chronic Q fever patients treated with antibiotics, and to assess patients' perception on treatment. Design: Cross-sectional study. Methods: LQOL was assessed with a validated questionnaire from the Nijmegen Clinical Screening Instrument. Patients' perception on treatment was measured with three newly developed questions. Results: We included 64 patients: LQOL was impaired in 55% (n ¼ 35) after a median follow-up of 5 years. Median treatment duration was 27 months. In multivariable analysis, treatment duration was significantly associated with impaired LQOL (OR 1.07; 95%CI 1.02-1.12, P < 0.01 per month increase). Age, gender, number of antibiotic regimens, surgical intervention, complications, diagnostic classification, focus of infection or registration of side effects during treatment were not associated with impaired LQOL. After start of treatment, 17 patients (27%) perceived improvement of their condition. Disadvantages of treatment were experienced on a daily basis by 24 patients (69%) with impaired LQOL and 13 patients (46%) without impaired LQOL (P ¼ 0.04). Conclusions: LQOL in chronic Q fever patients treated with antibiotics is impaired in more than half of patients 5 years after diagnosis. Antibiotic treatment duration was the only variable associated with impaired LQOL. The majority of patients experienced disadvantages on a daily basis, highlighting the high burden of disease and treatment.
Introduction
Between 2007 and 2010, the Netherlands faced the largest Q fever outbreak ever recorded, with over 4000 reported and 40 000 estimated cases of primary infected patients. 1 Q fever is caused by Coxiella burnetii, an intracellular bacterium that can be spread through air by cattle, mostly goats and sheep, after for example shedding in milk, excreta or birth products. 2 Besides symptomatic primary infection, long-term consequences consist of severe fatigue in 10-40% and chronic infection in approximately 1-5% of patients that were primarily infected. 3, 4 Most common manifestations of chronic Q fever are endocarditis, infected aneurysms or infected vascular prostheses. It mandates long-term antibiotic treatment, for at least 18 months. 1, 2 Treatment is initiated to reduce morbidity and mortality and to increase quality of life (QOL). First-line treatment for chronic Q fever consists of doxycycline and hydroxychloroquine with doxycycline and quinolones as alternative option, e.g. in case of intolerance due to side effects. 5 Besides antibiotic treatment, a significant proportion of chronic Q fever patients requires surgical intervention to remove infected prosthetic material or to treat complications. 2 However, treatment itself is often accompanied by serious toxicity such as gastro-intestinal complaints, photosensitivity, retinopathy and hyperpigmentation. [5] [6] [7] One small study performed in 26 patients with vascular chronic Q fever, showed that physical health scores declined during treatment, while mental health scores improved. 8 Long-term QOL (LQOL) in chronic Q fever patients who were treated with antibiotics has not been studied before. Our aim was to identify patient and treatment-related factors associated with impaired LQOL in these patients and to assess patients' perception on treatment.
Materials and methods

Study design and population
We performed a cross-sectional study to identify patient and treatment-related factors associated with impaired LQOL in chronic Q fever patients treated with antibiotics and to assess patients' perception on antibiotic treatment.
Chronic Q fever was defined according to the Dutch chronic Q fever consensus group criteria, 9 see Supplementary Table S1 .
Patients with proven or probable chronic Q fever according to the Dutch chronic Q fever consensus guidelines 18 years of age were considered eligible. 9 Patients with possible chronic Q fever were excluded, since these patients do not have an established infection and do not have an indication for treatment with antibiotics. This study was designed in cooperation with researchers from the Radboudumc of the ImpaQt study, which is a study on long-term psychosocial functioning in chronic Q fever patients (Reukers et al., ImpaQt study, unpublished data). All patients in the ImpaQt study were recruited via their (former) treating physicians from the Radboudumc in Nijmegen, Jeroen Bosch Hospital in 's-Hertogenbosch, Sint Elisabeth Hospital in Tilburg, and Bernhoven Hospital in Uden (all hospitals located in the center of the epidemic area during the 2007-10 outbreak). Additionally, we approached patients via the newsletter of the patient organization ('Q-uestion') to recruit patients from other hospitals. The data collection started in February 2016 and ended in December 2016. Design of the ImpaQt study was approved by the Medical Ethics Committee of the Radboud university medical center, design of this study was approved by the Medical Ethics Committee of the University Medical Center Utrecht.
Data collection
Patients gave consent to answer questionnaires on LQOL for both the ImpaQt study and the current study, and for retrieval of their clinical data from the Dutch national chronic Q fever database to match clinical data with LQOL data. LQOL and clinical data were matched using an anonymous identifier. In the chronic Q fever database, clinical, microbiological and radiological data are stored of all known proven, probable and possible chronic Q fever patients 18 years of age. Data are collected anonymously, all patients with serologically confirmed disease are therefore registered resulting in a complete overview. For additional details on design of this database, we refer to a previous article. 10 The threshold for excluding variables in the model was set at a P values of 0.10. Since this is an exploratory study, all patient and treatment related variables potentially influencing QOL on theoretical grounds were entered in the model. The selected variables were age, gender, presence of comorbidities, diagnostic classification (proven or probable chronic Q fever), focus of infection, presence of complications, surgical treatment of chronic Q fever, number of antibiotic treatment regimens, duration of treatment in months and reporting of side effects during treatment. Comorbidity was defined as having a history of diabetes mellitus, ischemic cardiovascular disease, cerebrovascular disease, peripheral arterial disease, immunodeficiency, vascular prosthesis or arterial aneurysm, valvulopathy or valve prosthesis, chronic obstructive pulmonary disease (COPD), malignancy (both nonhematological and hematological), renal insufficiency or heart failure. Odds ratios with 95% (profiling likelihood) confidence intervals were reported. The significance level was set at a P values <0.05. Missing data were reported below tables.
Results
Inclusion of patients
In total, 249 proven chronic Q fever patients and 74 probable chronic Q fever patients were identified for inclusion in the chronic Q fever database. At start of this study, 212 were known to be alive, of which 145 patients (68%) were approached via the four hospitals involved in this study. Overall response rate of recruitment via hospitals and the newsletter was 33% (69 patients). Of these 69 patients, 5 were excluded from analysis (they did not receive antibiotic treatment for unknown reasons). Therefore, we had data of 64 patients available for analysis: 52 with proven chronic Q fever (81%) and 12 with probable chronic Q fever (19%), see Figure 1 .
Baseline characteristics
Median age for all patients was 72 years [interquartile range (IQR) 65-79] and 84% of patients (n ¼ 54) were male. Any comorbidity was present in 52 patients (81%), most frequently arterial aneurysms or vascular prostheses (n ¼ 32; 50%), ischemic cardiovascular diseases (n ¼ 19; 30%) and valvulopathy or valve prostheses (n ¼ 13; 20%). Focus of chronic Q fever was vascular in 40 patients (63%), endocarditis in 10 patients (16%) and a combination of both in 9 patients (14%). Median time since diagnosis of chronic Q fever was 5.0 years (IQR 2.7-5.9 years). Most patients were treated with tetracyclines plus hydroxychloroquine (n ¼ 61; 95%), little over half of patients had finished antibiotic treatment at time of inclusion in our study (n ¼ 34; 53%) see Table 1 .
LQOL and factors predicting impaired LQOL
LQOL was impaired in 35 patients (55%). Median NCSI score for those with normal LQOL was 7 (IQR 4-10), and 29 (IQR 20-39) for those with impaired LQOL. In multivariable analysis, treatment duration was significantly associated with impaired LQOL (OR 1.07; 95%CI 1.02-1.12 per month increase, P < 0.01) and probable chronic Q fever patients showed a trend towards a higher risk for impaired LQOL (OR 4.08; 95%CI 0.94-22.91, P ¼ 0.08). None of the other factors were significantly associated with impaired LQOL (Table 2 ).
In patients that had finished antibiotic treatment at the time of inclusion with impaired LQOL (n ¼ 17), reasons for stopping treatment were sufficient response (n ¼ 10, 59%), refusal of further treatment by the patient (n ¼ 3, 18%), side effects (n ¼ 1, 6%) and unknown (n ¼ 3, 18%). In patients that had finished antibiotic treatment at the time of inclusion with normal LQOL (n ¼ 16), reasons for stopping treatment were sufficient response (n ¼ 13, 81%), refusal of further treatment by the patient (n ¼ 1, 6%), the fact that the clinician doubted the diagnosis (n ¼ 1, 6%) and unknown (n ¼ 1, 6%). Data with regard to LQOL were missing in one patient that had finished antibiotic treatment, the reason for stopping treatment was the presence of side effects in this patients.
Patients' perception on antibiotic treatment
After start of treatment, 17 patients (27%) experienced improvement of their condition during treatment compared to prior to start of treatment, 23 patients (36%) did not notice any change and 20 patients (32%) experienced deterioration of their condition during treatment compared to prior to start of treatment. Patients with impaired LQOL experienced more often a large deterioration in their condition after start of treatment (n ¼ 10; 29%) compared to those with normal LQOL (n ¼ 1; 4%), this difference showed a trend towards significance (P ¼ 0.05). In total, 22 patients (34%) judged that advantages of treatment did outweigh the disadvantages, without significant differences between those with and without impaired LQOL. Patients that had finished antibiotic treatment answered more often that disadvantages did not outweigh advantages (n ¼ 10/31; 32%) compared to those that were still on antibiotic treatment (n ¼ 4/30; 13%,), with a trend towards significance (P ¼ 0.10). Median treatment duration was not significantly different between those that had finished and were still on antibiotic treatment (25 months vs. 29 months, P ¼ 0.45). Disadvantages of treatment were experienced on a daily basis by 38 patients (59%) while 9 patients (14%) never experienced any disadvantages. In those with impaired LQOL, a significant higher proportion experienced disadvantages on a daily basis compared to patients with normal LQOL (n ¼ 24; 69% vs. n ¼ 13; 46%, P ¼ 0.04), while a relatively large proportion of patients with normal quality of life never perceived any disadvantages (Table 3 ). 
Discussion
LQOL is impaired in more than half of proven and probable chronic Q fever patients that were treated with antibiotics.
Treatment duration was the only variable that was associated significantly with impaired LQOL. Diagnostic classification as probable chronic Q fever was associated with a near-significant higher risk for impaired LQOL. Comorbidity, age, gender, surgical intervention, presence of complications, number of antibiotic regimens or reported side effects of antibiotic treatment were not associated with LQOL. The association between treatment duration and impaired LQOL could be due to the fact that treatment duration is a proxy parameter for disease severity, which may influence LQOL. Another potential explanation could be that treatment itself influences LQOL, apart from the disease, for example by causing side effects. Patients with probable chronic Q fever had a trend towards a higher risk of impaired LQOL. This is remarkable, since none of these patients had complications or underwent surgical intervention for their disease and comorbidities were not present more often in these patients. The higher risk for impaired LQOL in probable chronic Q fever patients, the absence of an association between surgical interventions or presence of complications supports the hypothesis that treatment itself may influence LQOL: these variables can all be considered to be proxy parameters for severity of disease. It is currently unknown if all probable chronic Q fever patients should be treated with antibiotics. A proportion of patients develop complications and are at risk of chronic Q fever-related mortality, while a large number of probable chronic Q fever patients do not develop complications at all. 5 Further studies identifying factors that are associated with disease-related events in probable chronic Q fever patients specifically are needed, to enable a more targeted selection of patients at risk for those events and an indication for antibiotic treatment. Although reporting of any side effects to the treating physician during treatment was not associated with LQOL, the proportion of patients reporting side effects on a daily basis in this study was higher among those with impaired LQOL, which supports the hypothesis of a negative influence on LQOL of treatment. The difference in patient-reported and 'doctor-reported' side effects may be explained by recall bias: patients with worse LQOL may have a better recall of disadvantages and report side effects more often or more intense than those with a normal quality of life (while there may have been no actual difference during treatment). Probably, LQOL in chronic Q fever patients is influenced by many factors. It is very well possible that both disease severity and perception of treatment play an important role in LQOL of chronic Q fever patients. This study highlights the large impact of chronic Q fever on LQOL, besides the high morbidity and mortality. 5 Because of the high risk for mortality and complications, treatment is inevitable. Nevertheless, awareness of the consequences of the disease and its treatment on LQOL among clinicians is crucial: impaired QOL may have a bigger impact on patients than clinical outcomes, and acknowledgement of disease burden and disadvantages of treatment is important for patients. 15 The importance of acknowledgement of the consequences of the Q fever outbreak is painfully visible in the Netherlands, where patients have sued the Dutch government and goat farmers after the Q fever outbreak of 2007-10. They were accused of negligence and mismanagement, patients felt misinformed and unacknowledged with regard to the impact of the disease on their lives. 16 The current study was conducted shortly before start of the juridical trial. However, it is possible that our study results may be influenced by the ongoing public debate. Our study has several strengths. Data on QOL in chronic Q fever patients are scarce and the patients' perception on treatment of chronic Q fever was not described previously. Furthermore, we had the opportunity to assess clinical characteristics and their relation to the outcome, thanks to the extensive Dutch national chronic Q fever database, which contains detailed medical data of all chronic Q fever patients.
In this study, we did not use a comparison group. Very few patients were not treated with antibiotics, and those who are left untreated often do not have comparable disease severity (e.g. patients with possible chronic Q fever or probable chronic Q fever based on a risk factor without any symptoms or signs of infection). LQOL data were available for five patients: 80% (n ¼ 4) reported impaired LQOL. However, we did not aim to recruit these patients. Therefore, they are probably not representative for the group of untreated patients. In general, untreated patients are incomparable in terms of prognosis and disease burden. Therefore, it was impossible to assess the effect of treatment itself on LQOL. To our knowledge, LQOL has not been studied in patients with endocarditis or infected vascular prostheses by other pathogens. Therefore, it is difficult to compare the impact of the disease to other comparable conditions. Furthermore, we did not compare the influence of different antibiotic regimens on LQOL: most patients used multiple regimens consecutively, and numbers per subgroup were small. Because of the retrospective design of this study and the fact that 53% of patients had finished antibiotic treatment at the time of inclusion, there is a considerable risk of recall bias in this study. Moreover, questions regarding patients' perception on treatment have not been validated in prior studies, thus interpretation of these questions should be done cautiously. However, the answers to these questions provide an interesting insight in patients' perception during treatment and demonstrate the burden of treatment experienced by these patients. Finally, the response rate was 33%. Therefore, it is possible that there is a selection bias caused by selective response which may distort the results of this study in both directions.
LQOL in proven and probable chronic Q fever patients receiving antibiotic treatment is impaired in more than half of patients 5 years after diagnosis. Antibiotic treatment duration was the only variable that was associated with impaired QOL. The majority of patients did not notice improvement of their condition after start of treatment and most patients experienced disadvantages on a daily basis, highlighting the high burden of disease and treatment in these patients.
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